Pearl Huang

Pearl Huang is an accomplished biotechnology executive currently serving as the CEO and President of Dunad Therapeutics since May 2022, and as a Non-Executive Director at both BB Biotech and Waters Corporation since January 2022. Previously, Pearl held the role of CEO at Cygnal Therapeutics from January 2019 to June 2022 and served as SVP, Head of Therapeutic Modalities at Roche from December 2014 to December 2018, overseeing a multinational drug discovery organization. Pearl's extensive experience includes leadership positions at GlaxoSmithKline, Beigene Bio, Merck and Co., and GSK, spanning areas from oncology to drug portfolio management. Pearl earned a Doctor of Philosophy (Ph.D.) in Molecular Biology from Princeton University and a Bachelor of Science in Life Sciences from the Massachusetts Institute of Technology.